Initial and maintenance combination treatment with interferon-β, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma

Combined treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy was assessed in patients with malignant glioma who had not received previous cytotoxic drug therapy. Forty-three patients up to 75 years old with histopathologically confirmed malignant glioma were studied. All patients ha...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuro-oncology Vol. 49; no. 1; pp. 57 - 62
Main Authors:	WAKABAYASHI, Toshibiko, HATANO, Norikazu, KAJITA, Yasukazu, YOSHIDA, Tazuka, MIZUNO, Masaaki, TANIGUCHI, Katumi, OHNO, Takanari, NAGASAKA, Tetsurou, YOSHIDA, Jun
Format:	Journal Article
Language:	English
Published:	Dordrecht Springer 01-08-2000
Subjects:	Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Brain Neoplasms - diagnostic imaging Brain Neoplasms - drug therapy Brain Neoplasms - radiotherapy Child Child, Preschool Combined Modality Therapy Female Glioma - diagnostic imaging Glioma - drug therapy Glioma - radiotherapy Humans Interferon-beta - administration & dosage Male Medical sciences Middle Aged Neurology Nitrosourea Compounds - administration & dosage Survival Analysis Tomography, X-Ray Computed Treatment Outcome Tumors of the nervous system. Phacomatoses Antineoplastic agent Human Intracranial Nervous system diseases Prognosis Nitrosoureas Cytokine Malignant tumor Radiotherapy Cerebral disorder Malignant glioma Chemotherapy Central nervous system disease Beta interferon Combined treatment Ranimustine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Combined treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy was assessed in patients with malignant glioma who had not received previous cytotoxic drug therapy. Forty-three patients up to 75 years old with histopathologically confirmed malignant glioma were studied. All patients had tumors measurable by neuroimaging, a Karnofsky performance score exceeding 40, and an expected survival exceeding 2 months. A response rate of 49% (21/45) was observed, including 6 complete remissions (14%) and 15 partial remissions (35%). Of the 43 patients who completed initial therapy, 19 were given sequential maintenance therapy. Survival time was much longer with than without maintenance therapy. Toxic side effects were moderate and did not substantially affect patients' general condition. We concluded that this combination therapy had a pronounced effect on untreated malignant glioma, particularly in patients whose initial therapy was followed up with maintenance therapy.
ISSN:	0167-594X 1573-7373
DOI:	10.1023/A:1006405512579